Mesoblast Ltd MESO

NAS: MESO | ISIN: US5907171046 30/04/2025

11,40 USD (-4,28%)

(-4,28%) 30/04/2025

Toon enkel gratis nieuws

9 maart 2021 · Mesoblast Closes US$110/A$138 Million Financing Led by US Strategic Investor Group · Persbericht

17 februari 2021 · Positive Outcomes of First Children Treated With Remestemcel-L for Multisystem Inflammatory Syndrome (MIS-C) and Heart Failure Post-COVID-19 Published in Pediatrics · Persbericht

11 februari 2021 · Mesoblast Phase 3 Trial Shows That a Single Injection of Rexlemestrocel-L + Hyaluronic Acid Carrier Results in at Least Two Years of Pain Reduction With Opioid Sparing Activity in Patients With Chronic Low Back Pain Due to Degenerative Disc Disease · Persbericht

10 februari 2021 · Mesoblast Corporate Update · Persbericht

11 januari 2021 · Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference · Persbericht

11 januari 2021 · Single Dose of Rexlemestrocel-L Provides Substantial and Durable Reduction in Heart Attacks, Strokes and Cardiac Death in Patients With Chronic Heart Failure · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe